RhumbLine Advisers’s Marker Therapeutics MRKR Stock Holding History

RhumbLine Advisers’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,531	Closed	-$57K	–	3067
2021 Q1	$57K	Buy	2,531 +10	+0.4%	+$229	﹤0.01%	2972
2020 Q4	$37K	Buy	2,521 +334	+15%	+$5.18K	﹤0.01%	3028
2020 Q3	$33K	Sell	2,187 -878	-29%	-$16K	﹤0.01%	2963
2020 Q2	$63K	Buy	3,065 +852	+38%	+$18.6K	﹤0.01%	3016
2020 Q1	$42K	Hold	2,213	–	–	﹤0.01%	2874
2019 Q4	$64K	Buy	2,213 +39	+2%	+$1.42K	﹤0.01%	2907
2019 Q3	$111K	Buy	2,174 +106	+5%	+$6.26K	﹤0.01%	2868
2019 Q2	$164K	Buy	+2,068	New	+$123K	﹤0.01%	2837

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's MRKR Position: Q2 2021 in Review

RhumbLine Advisers sold out of Marker Therapeutics (MRKR) in Q2 2021, closing a stake of 2,531 shares — an estimated $57K sold.

RhumbLine Advisers first reported a position in MRKR in Q2 2019 and held it in 8 quarters. The position peaked at $164K in Q2 2019. 74 funds tracked by Wall St. Rank hold MRKR as of Q2 2021.

RhumbLine Advisers reported no remaining Marker Therapeutics position as of Q2 2021 after selling out during the quarter.
RhumbLine Advisers sold 2,531 Marker Therapeutics shares in Q2 2021, an estimated $57K.
RhumbLine Advisers first reported a position in Marker Therapeutics in Q2 2019 and held it in 8 quarters.
RhumbLine Advisers's Marker Therapeutics position peaked at $164K in Q2 2019.
74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.